Patent intelligence · US
US 12220447
Proteolytic enzyme composition
Proteolytic enzyme composition
Patent details — US 12220447
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 11, 2025
- Expiration
- Feb 6, 2045
- Applicant
- Bright Lifecare PVT LTD.
- Claims
- 5
- CPC classes
- A61K, A61K38/465, A61K38/47, A61K38/48
Quick answer
US 12220447 (Proteolytic enzyme composition) is held by Bright Lifecare PVT LTD.. Status: granted. Granted Feb 11, 2025. Expires Feb 6, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Bright Lifecare PVT LTD.
- Grant date
- Expiration
- Claims
- 5
- CPC classes
- A61K, A61K38/465, A61K38/47, A61K38/48, A61K38/4826, A61K38/4873
More from Bright Lifecare PVT LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12383631
Immune antigen specific IL-18 immunocytokines and uses thereof
granted -
US 12350120
Gum-protecting and teeth-whitening strip and preparation method thereof
granted -
US 12215133
GIP and GLP-1 dual receptor agonist, pharmaceutical composition, and use
granted -
US 12173062
Modified TNF-α antibodies and uses thereof
granted -
US 12115136
Fortified CBD oil for treatment of PTSD
granted -
US 12097230
Method and composition for treating post operative conditions
granted -
US 11925686
Materials for phototherapies of ophthalmic diseases
granted
Frequently asked questions
What is US patent 12220447?
US 12220447 (Proteolytic enzyme composition) is held by Bright Lifecare PVT LTD.. Status: granted. Granted Feb 11, 2025. Expires Feb 6, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12220447?
Bright Lifecare PVT LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 57 pharmaceutical patents for this assignee.
When does US 12220447 expire?
Our index shows an expiration date of Feb 6, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.